GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (FRA:ZOE) » Definitions » Cyclically Adjusted PS Ratio

Zoetis (FRA:ZOE) Cyclically Adjusted PS Ratio : 10.93 (As of Apr. 30, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zoetis Cyclically Adjusted PS Ratio?

As of today (2024-04-30), Zoetis's current share price is €148.78. Zoetis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €13.61. Zoetis's Cyclically Adjusted PS Ratio for today is 10.93.

The historical rank and industry rank for Zoetis's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:ZOE' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.58   Med: 12.97   Max: 19.62
Current: 10.5

During the past years, Zoetis's highest Cyclically Adjusted PS Ratio was 19.62. The lowest was 9.58. And the median was 12.97.

FRA:ZOE's Cyclically Adjusted PS Ratio is ranked worse than
93.5% of 739 companies
in the Drug Manufacturers industry
Industry Median: 2.09 vs FRA:ZOE: 10.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zoetis's adjusted revenue per share data for the three months ended in Dec. 2023 was €4.411. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €13.61 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Zoetis Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Zoetis's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zoetis Cyclically Adjusted PS Ratio Chart

Zoetis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 14.64 19.24 10.41 12.98

Zoetis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.41 11.51 11.63 11.51 12.98

Competitive Comparison of Zoetis's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zoetis's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zoetis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zoetis's Cyclically Adjusted PS Ratio falls into.



Zoetis Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Zoetis's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=148.78/13.61
=10.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zoetis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Zoetis's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=4.411/129.4194*129.4194
=4.411

Current CPI (Dec. 2023) = 129.4194.

Zoetis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 1.584 99.695 2.056
201406 1.699 100.560 2.187
201409 1.869 100.428 2.409
201412 2.127 99.070 2.779
201503 2.024 99.621 2.629
201506 2.093 100.684 2.690
201509 2.156 100.392 2.779
201512 2.336 99.792 3.030
201603 2.089 100.470 2.691
201606 2.155 101.688 2.743
201609 2.221 101.861 2.822
201612 2.438 101.863 3.098
201703 2.324 102.862 2.924
201706 2.286 103.349 2.863
201709 2.295 104.136 2.852
201712 2.513 104.011 3.127
201803 2.262 105.290 2.780
201806 2.485 106.317 3.025
201809 2.611 106.507 3.173
201812 2.838 105.998 3.465
201903 2.665 107.251 3.216
201906 2.839 108.070 3.400
201909 2.987 108.329 3.569
201912 3.137 108.420 3.745
202003 2.898 108.902 3.444
202006 2.875 108.767 3.421
202009 3.169 109.815 3.735
202012 3.102 109.897 3.653
202103 3.289 111.754 3.809
202106 3.390 114.631 3.827
202109 3.551 115.734 3.971
202112 3.660 117.630 4.027
202203 3.804 121.301 4.059
202206 4.117 125.017 4.262
202209 4.310 125.227 4.454
202212 4.126 125.222 4.264
202303 4.021 127.348 4.086
202306 4.347 128.729 4.370
202309 4.368 129.860 4.353
202312 4.411 129.419 4.411

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zoetis  (FRA:ZOE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Zoetis Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Zoetis's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zoetis (FRA:ZOE) Business Description

Industry
Address
10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Zoetis (FRA:ZOE) Headlines

No Headlines